ReviewOncology reports2022
Circular RNAs in endometrial carcinoma (Review).
Review in Oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Exploring the role of circular RNAs in endometrial cancer progression and chemoresistance: Implications for targeted therapies.European journal of medical research · 2025Review
- Hsa_circ_0005571 promotes the proliferation and invasion of colorectal cancer cells.Scientific reports · 2025Article
- Circular RNAs in gynecological cancer: From molecular mechanisms to clinical applications (Review).Oncology letters · 2025Review
- MECOM and the PRDM gene family in uterine endometrial cancer: bioinformatics and experimental insights into pathogenesis and therapeutic potentials.Molecular medicine (Cambridge, Mass.) · 2024Article
- Deciphering the role of SAMHD1 in endometrial cancer progression.Biology direct · 2024Article
- circRNAs in Endometrial Cancer-A Promising Biomarker: State of the Art.International journal of molecular sciences · 2024Review
- XRCC1 and hOGG1 polymorphisms and endometrial carcinoma: A meta-analysis.Open medicine (Warsaw, Poland) · 2024Review
- Number of Positive Lymph Nodes and Survival in Endometrial Carcinoma: A Proposal for a Modified Staging.International journal of women's health · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the leading causes of death in women in Western developed countries, endometrial carcinoma (EC) is a common gynecological malignant tumor that seriously threatens women's health. In recent years, a trend has emerged of EC being manifested in younger women, and its overall incidence is gradually rising. Circular RNAs (circRNAs) are novel endogenous transcripts that have limited ability to encode proteins due to their covalent closed‑loop structure, which differs from that of other types of RNA. A growing body of evidence has demonstrated that circRNAs fulfill an important role in lung cancer, gastric cancer, breast cancer, EC and other malignant tumor types, and they can affect the occurrence and development of these malignancies through a variety of pathways, further demonstrating the potential of circRNAs as molecular biomarkers for the diagnosis, treatment and prognosis of malignant tumors. The purpose of the present review is to summarize the current understanding of the biogenesis and effects of circRNAs, and to discuss the expression, function and underlying mechanism of circRNAs in EC in order to identify potential novel biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.